NCT01486381View on ClinicalTrials.gov

Long Term Safety of Biphasic Insulin Aspart 30 in Juveniles With Type 1 Diabetes

PHASE3CompletedINTERVENTIONAL

Enrollment

22

Participants

Timeline

Start Date

March 20, 2002

Primary Completion Date

May 30, 2003

Study Completion Date

May 30, 2003

Conditions

DiabetesDiabetes Mellitus, Type 1

Interventions

DRUG

biphasic insulin aspart 30

Administered subcutaneously (s.c., under the skin)

Trial Locations (2)

7925

Novo Nordisk Investigational Site, Cape Town

0001

Novo Nordisk Investigational Site, Pretoria

Sponsors

Lead Sponsor

Novo Nordisk A/S

All Listed Sponsors

lead

Novo Nordisk A/S

INDUSTRY